Older man flexing his muscle while drinking coffee

(Photo by Cast Of Thousands on Shutterstock)

In A Nutshell

  • A protein called NDRG1 builds up in aging muscle stem cells, acting like a brake on the body’s repair system, and that slowdown may not be an accident.
  • When researchers blocked NDRG1 in aged mice, muscles healed faster after one injury, but the stem cells died off more quickly and failed after repeated stress.
  • The body may be trading speed for survival, keeping a tougher reserve of stem cells around for the long haul rather than burning through them on quick repairs.
  • This was a mouse-only study, and a human application is still far off; but it raises a bigger question: what if some of what looks like aging is actually the body protecting itself?

Scientists have discovered something unexpected and counterintuitive in their quest to turn back the clock on aging muscle. When researchers restored youthful repair speed to aged muscle cells in mice, those cells became more fragile and prone to death. The finding raise a question that sounds almost nonsensical: could aging actually be protecting us?

A team at Stanford University School of Medicine, in collaboration with UCLA’s Broad Stem Cell Research Center, identified a protein called NDRG1 that accumulates in muscle stem cells as animals age. By blocking this protein, they successfully made old muscle cells behave young again. But the experiment revealed a troubling trade-off. Cells without NDRG1 died faster and recovered poorly from repeated injuries, suggesting that the slowdown we experience with age might be a survival mechanism rather than pure decline.

The work, published in Science, forces the field to reconsider how we approach anti-aging therapies. Quick fixes for one aging hallmark can create problems elsewhere, a pattern that has plagued longevity research for years.

The Protein That Slows Repair

Muscle stem cells are the body’s maintenance crew. They sit dormant until injury strikes, then spring into action to rebuild damaged fibers. In young animals, this response is swift. In older animals, it stalls, contributing to the weakness and frailty that define aging.

The Stanford-led team compared muscle stem cells from young mice and aged mice. They discovered that NDRG1, a protein found throughout the body, built up to 3.5 times higher levels in the cells of older animals. This protein acts as a brake on a cellular pathway that controls growth, division, and repair. High NDRG1 means the growth engine runs slower.

To test whether NDRG1 was responsible for the age-related slowdown, the team blocked the protein in aged mouse muscle stem cells. Both in laboratory dishes and in living animals, the results were telling. Cells without NDRG1 activated much faster, mimicking young cell behavior. When researchers injured the muscles of aged mice and inhibited NDRG1, muscle regenerated more quickly and efficiently than in untreated controls.

At that point, the experiment looked like a clear win for anti-aging science. Then the researchers kept looking.

aging muscle
Muscle tissue from aged mice seven days after injury. Left: Aged mice with normal NDRG1 levels show slower regeneration with smaller muscle fibers. Right: Aged mice in which NDRG1 was recently blocked show faster regeneration with larger fibers. (Credit: Jengmin Kang, Rando Lab)

The Survival Cost Nobody Expected

The team subjected mice to repeated muscle injuries spaced weeks apart to see how well the treated cells held up over time. Stem cells without NDRG1 showed significantly reduced survival rates. In mice treated to block the protein, regenerative capacity declined after multiple injuries. The cells that remained performed worse than cells in untreated aged mice.

The researchers identified what they call survivorship bias. Cells lacking NDRG1 tend to die under stress. The cells that persist in aged muscle, loaded with NDRG1, move slowly but prove resilient. Think of it as the body holding onto its repair crew rather than deploying everyone at once. Fewer workers get sent out, but the crew survives long enough to handle the next emergency. It is the stem cell pool itself being protected, not just the muscle tissue in the moment.

Aging, viewed this way, is not a straightforward decline in function. It is a shift toward a tougher population of cells that sacrifice speed for durability. The mouse data hint that slower activation may actually help stem cells survive repeated stress over time. If that pattern holds in people, it could reframe how we think about aging muscle entirely.

Studying Muscle Aging In Mice

The study used mice as the model for aging processes. Researchers isolated muscle stem cells from young mice and aged mice and confirmed that NDRG1 protein levels were 3.5 times higher in the older cells. They then blocked NDRG1 and measured how quickly the aged cells activated and divided. The results matched young cell behavior.

In living mice, the team induced muscle injuries using a chemical that damages muscle fibers without harming surrounding tissue. Some aged mice had NDRG1 blocked through genetic tools. Muscle healing was tracked using tissue analysis and functional tests of how well the muscle recovered. After a single injury, NDRG1-inhibited muscles healed faster. After repeated injuries spaced weeks apart, the treated groups showed weaker recovery and fewer surviving stem cells.

The study focused exclusively on mouse biology. No human data were included, which means the relevance to people remains unknown. Mouse muscles age much faster than human muscles, and factors like lifestyle and genetics could change how NDRG1 functions in people.

Lessons for Anti-Aging Medicine

The NDRG1 findings align with a broader pattern in longevity research. Overriding one aging mechanism often creates unexpected problems. Early gene therapies restored youthful traits in certain aging models, only to trigger complications later. Anti-aging drugs that work short-term can cause long-term damage. The NDRG1 story underscores why single wins fall short and why long-term testing matters.

It is worth noting that blocking a protein in a lab mouse relies on precise genetic engineering, a far cry from anything a person could take as a pill today. Any future human application would likely involve carefully timed, partial reductions in NDRG1 activity rather than switching it off entirely.

Similar protective brakes appear in stem cells found in the brain and blood, suggesting this could be a general aging strategy the body uses across different tissues. Future therapies might aim for balance rather than complete inhibition, using timed interventions to speed recovery without sacrificing the survival of the stem cell pool.

Older man wiping off sweat after a workout at the gym
Slow and steady: Older muscles appear to do more with less on a cellular level. (Photo by Mladen Zivkovic en Shutterstock)

The Trade-Off Between Speed and Survival

Aging is often cast as the enemy, a force to be defeated through biotechnology and clever interventions. The NDRG1 research suggests a more complex reality. The slowdown that defines aging muscle might not be pure decline. It might be how our bodies choose to endure.

The mice that had NDRG1 blocked regained youthful repair speed, but they became fragile under repeated stress. The aged mice that retained high NDRG1 recovered slowly but stayed robust. Neither outcome is simply better or worse. Each reflects a different survival strategy shaped by the demands of a longer life.

Researchers now face a more nuanced challenge than simply reversing aging hallmarks. The goal may be to find ways to recover some of the vigor of youth while keeping the resilience that age builds in. That balance, if achieved, could extend healthy years without stripping away the biological safeguards that quiet accumulation has put in place.


Disclaimer: This article is for general informational purposes only and is not intended as medical advice. Consult a qualified healthcare provider with any questions about your health.


Paper Notes

Limitations

This was an animal study conducted entirely in mice. No human subjects were involved, and the findings cannot be directly applied to people at this stage. Mouse muscle ages on a compressed timeline compared to human muscle, and the biological environment inside aging human tissue is considerably more complex, shaped by decades of lifestyle, diet, medication, and genetic variation. These differences mean that NDRG1’s role in people could look quite different from what was observed here.

The study examined NDRG1 in skeletal muscle stem cells specifically. Whether the same trade-off between repair speed and cell survival plays out in other tissues or other stem cell types in humans remains an open question, though the researchers note that similar protective proteins appear in brain and blood stem cells in other research contexts.

The experiments used genetic tools to block NDRG1 in mice, a method that is more precise and complete than any drug currently available for humans. A therapeutic approach in people would likely involve partial, targeted reduction of NDRG1 activity rather than full removal, and how cells respond to that more limited intervention is not yet known.

Sample sizes across the experiments were small, typically between three and five animals per group, which is standard for this type of controlled laboratory study but limits the statistical weight of individual findings. The results are internally consistent and replicated across multiple experimental designs, which strengthens confidence in the conclusions, but larger follow-up studies will be needed before the findings can be considered definitive.

The researchers also did not examine whether age, sex, or baseline health status of the mice affected how NDRG1 responded to injury or deletion. These variables could matter considerably when thinking about eventual human applications.

Funding and Disclosures

The research was supported by the National Research Foundation of Korea (grant RS-2025-00515310, supporting Jengmin Kang), the National Institutes of Health (grants AG36695, AG68667, and AG82764, supporting Thomas A. Rando), the NOMIS Foundation, the Milky Way Research Foundation, and the Hevolution Foundation. The authors declared no competing interests. RNA sequencing data from the study have been deposited in the NCBI Gene Expression Omnibus database and are publicly accessible under accession number GSE275358.

Publication Details

Full title: Cellular survivorship bias as a mechanistic driver of muscle stem cell aging | Authors: Jengmin Kang, Daniel I. Benjamin, Qiqi Guo, Chauncey Evangelista, Soochi Kim, Marina Arjona, Pieter Both, Mingyu Chung, Ananya K. Krishnan, Gurkamal Dhaliwal, Richard Lam, and Thomas A. Rando | Journal: Science | Volume and issue: Vol. 391, Issue 6784, p. 517 | Published: January 29, 2026 | DOI: 10.1126/science.ads9175 | Corresponding author: Thomas A. Rando, Stanford University School of Medicine ([email protected]) | Submitted: September 5, 2024 | Resubmitted: May 9, 2025 | Accepted: October 20, 2025

About StudyFinds Analysis

Called "brilliant," "fantastic," and "spot on" by scientists and researchers, our acclaimed StudyFinds Analysis articles are created using an exclusive AI-based model with complete human oversight by the StudyFinds Editorial Team. For these articles, we use an unparalleled LLM process across multiple systems to analyze entire journal papers, extract data, and create accurate, accessible content. Our writing and editing team proofreads and polishes each and every article before publishing. With recent studies showing that artificial intelligence can interpret scientific research as well as (or even better) than field experts and specialists, StudyFinds was among the earliest to adopt and test this technology before approving its widespread use on our site. We stand by our practice and continuously update our processes to ensure the very highest level of accuracy. Read our AI Policy (link below) for more information.

Our Editorial Process

StudyFinds publishes digestible, agenda-free, transparent research summaries that are intended to inform the reader as well as stir civil, educated debate. We do not agree nor disagree with any of the studies we post, rather, we encourage our readers to debate the veracity of the findings themselves. All articles published on StudyFinds are vetted by our editors prior to publication and include links back to the source or corresponding journal article, if possible.

Our Editorial Team

Steve Fink

Editor-in-Chief

John Anderer

Associate Editor

Leave a Reply